1. Home
  2. RPRX vs AMCR Comparison

RPRX vs AMCR Comparison

Compare RPRX & AMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RPRX
  • AMCR
  • Stock Information
  • Founded
  • RPRX 1996
  • AMCR 1926
  • Country
  • RPRX United States
  • AMCR Switzerland
  • Employees
  • RPRX N/A
  • AMCR N/A
  • Industry
  • RPRX Biotechnology: Pharmaceutical Preparations
  • AMCR Miscellaneous manufacturing industries
  • Sector
  • RPRX Health Care
  • AMCR Consumer Discretionary
  • Exchange
  • RPRX Nasdaq
  • AMCR Nasdaq
  • Market Cap
  • RPRX 16.2B
  • AMCR 18.8B
  • IPO Year
  • RPRX 2020
  • AMCR N/A
  • Fundamental
  • Price
  • RPRX $40.42
  • AMCR $8.07
  • Analyst Decision
  • RPRX Strong Buy
  • AMCR Buy
  • Analyst Count
  • RPRX 3
  • AMCR 8
  • Target Price
  • RPRX $46.00
  • AMCR $10.40
  • AVG Volume (30 Days)
  • RPRX 2.8M
  • AMCR 25.9M
  • Earning Date
  • RPRX 11-05-2025
  • AMCR 11-05-2025
  • Dividend Yield
  • RPRX 2.18%
  • AMCR 6.32%
  • EPS Growth
  • RPRX N/A
  • AMCR N/A
  • EPS
  • RPRX 1.77
  • AMCR 0.32
  • Revenue
  • RPRX $2,349,553,000.00
  • AMCR $17,401,000,000.00
  • Revenue This Year
  • RPRX $36.16
  • AMCR $53.83
  • Revenue Next Year
  • RPRX $2.04
  • AMCR $1.17
  • P/E Ratio
  • RPRX $22.85
  • AMCR $25.16
  • Revenue Growth
  • RPRX 3.69
  • AMCR 28.42
  • 52 Week Low
  • RPRX $24.05
  • AMCR $7.67
  • 52 Week High
  • RPRX $41.00
  • AMCR $10.71
  • Technical
  • Relative Strength Index (RSI)
  • RPRX 74.39
  • AMCR 48.40
  • Support Level
  • RPRX $35.92
  • AMCR $7.75
  • Resistance Level
  • RPRX $37.40
  • AMCR $8.41
  • Average True Range (ATR)
  • RPRX 1.09
  • AMCR 0.17
  • MACD
  • RPRX 0.26
  • AMCR -0.00
  • Stochastic Oscillator
  • RPRX 91.94
  • AMCR 54.36

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

About AMCR Amcor plc

Amcor is a global producer of plastic packaging primarily for the fast-moving consumer goods industry. About 90% of earnings are exposed to the flexible packaging business. This is soft disposable plastic for a variety of food, drink, healthcare, and hygiene products. The remainder of earnings are from the Latin and North American rigids business, which is primarily beverage bottling for the soft drink industry. Operating in more than 35 countries, Amcor has market share in its established regions of North America, Latin America, Europe, and Asia-Pacific. About half of group sales are derived from North America and the remainder is split equally between Western Europe and emerging markets. Australia and New Zealand sales make up less than 5% of group sales.

Share on Social Networks: